[A16-54] Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 16.11.2016
Project no.:
A16-54
Commission:
Commission awarded on 15.08.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-35 | Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A19-85 | Trifluridine/tipiracil (gastric cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-77 | Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A16-54 | Commission completed |
Federal Joint Committee (G-BA)
2017-02-02 A G-BA decision was published.